| |
Remdesivir- An Update from Gilead Chairman & CEO Daniel O'Day
|
| |
| |
From: Advocacy at Gilead Sciences
To: Advocacy at Gilead Sciences
Subject: An Update from Gilead Chairman & CEO Daniel O'Day
Date: April 4, 2020 at 6:32:19 PM EDT
Download the PDF here
To our community partners,
A short time ago, Gilead Chairman and CEO Daniel O'Day shared an update about our ongoing work with regulatory authorities worldwide to provide investigational remdesivir for emergency use to treat patients with severe COVID-19 disease, under expanded access programs and the multiple clinical trials we are supporting globally. The update also discusses our efforts to increase available supply as quickly as possible should the data from those trials be positive.
Remdesivir is an investigational medicine that has not been approved anywhere globally, and it is not yet known if remdesivir is safe and effective for the treatment of COVID-19. If remdesivir is proven to be safe and effective to treat COVID-19, we are committed to making the drug both accessible and affordable to governments and patients around the world. As stated in the update, we commit to providing all of our current supply of remdesivir at no cost for use in clinical trials, compassionate use and expanded access programs, and following potential future regulatory authorizations globally.
Please read the attached update for details on the work we're doing to help patients now and in the future.
Thank you,
Gilead Sciences Advocacy Team
|
|
| |
| |
|
|
|
